Modality
Degrader
MOA
C5i
Target
PARP
Pathway
RNA Splicing
Crohn'sGISTET
Development Pipeline
Preclinical
~Apr 2010
→ ~Jul 2011
Phase 1
~Oct 2011
→ ~Jan 2013
Phase 2
~Apr 2013
→ ~Jul 2014
Phase 3
~Oct 2014
→ ~Jan 2016
NDA/BLA
~Apr 2016
→ ~Jul 2017
Approved
Oct 2017
→ Jan 2027
ApprovedCurrent
NCT07794647
1,932 pts·GIST
2017-10→TBD·Terminated
NCT05317949
2,008 pts·ET
2025-12→2027-01·Completed
3,940 total pts2 indications
CompletedCurrentUpcoming
Catalysts (1)
2027-01-019mo awayPh3 Readout· ET
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
Approved
Termina…
Approved
Complet…
Catalysts
Ph3 Readout
2027-01-01 · 9mo away
ET
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07794647 | Approved | GIST | Terminated | 1932 | SRI-4 |
| NCT05317949 | Approved | ET | Completed | 2008 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| CRS-337 | CRISPR Therapeutics | Phase 2/3 | PARP | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Lisonesiran | Arvinas | Phase 1/2 | PARP | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C |